Corticotropin releasing factor 2 receptor agonists
View Patent ↗Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
1. An isolated antibody specific for a non-native peptide, wherein the non-native peptide comprises the sequence
ZGPPISIDLPX 11 X 12 LLRKX 17 IEIEKQEKEKQQAX 31 X 32 NAX 35 X 36 LX 38 X 39 X 40 (SEQ ID NO:531), wherein:
X 11 is selected from F, Y, L, I, and T;
X 12 is selected from Q, W, and Y;
X17 is selected from V and M;
X 31 is selected from T and A;
X 32 is selected from N and T;
X 35 is selected from R and L;
X 36 is selected from L and I;
X 38 is selected from D and A;
X 39 is selected from T and R; and
X 40 is selected from I and V;
or variants thereof having at least about 95% sequence identity to said peptide.
2. The antibody according to claim 1 , wherein the variant has at least about 97% sequence identity to said non-native peptide.
3. The antibody according to claim 1 , wherein X 11 is selected from F, L, T, and Y.
4. The antibody according to claim 1 , wherein X 11 X 12 are selected from the group consisting of FQ, YQ, YW, LQ, LY, IY, and TY.
5. The antibody according to claim 4 , wherein X 31 X 32 are selected from the group consisting of AN and TT.
6. The antibody according to claim 5 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.
7. The antibody according to claim 5 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
8. The antibody according to claim 4 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.
9. The antibody according to claim 4 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
10. The antibody according to claim 1 , wherein X 32 X 33 are selected from the group consisting of AN and TT.
11. The antibody according to claim 10 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.
12. The antibody according to claim 11 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
13. The antibody according to claim 10 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
14. The antibody according to claim 1 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.
15. The antibody according to claim 14 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
16. The antibody according to claim 1 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.
17. The antibody according to claim 1 , wherein the non-native peptide comprises a sequence selected from the group consisting of SEQ ID NO: 22, 144, 148, 149, 151, 278, 279, 286, 288, 311, 349, 350, 351, 352, and 353.
18. The antibody according to claim 1 , wherein the antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, chimeric antibodies, human antibodies, single chain antibodies, Fab fragments, F(ab′) 2 fragments, molecules produced using a Fab expression library, human polyclonal antibodies produced in transgenic mice, human monoclonal antibodies produced in transgenic mice, and epitope binding fragments thereof.
19. An isolated antibody specific for a non-native peptide, wherein the non-native peptide comprises the sequence
ZGPPISIDLPX 11 X 12 LLRKX 17 IEIEKQEKEKQQAX 31 X 32 NAX 35 X 36 LX 38 X 39 X 40 (SEQ ID NO:531), wherein:
X 11 is selected from F, Y, L, I, and T;
X 12 is selected from Q, W, and Y;
X17 is selected from V and M;
X 31 is selected from T and A;
X 32 is selected from N and T;
X 35 is selected from R and L;
X 36 is selected from L and I;
X 38 is selected from D and A;
X 39 is selected from T and R; and
X 40 is selected from I and V.
20. An isolated antibody specific for a non-native peptide, wherein the non-native peptide comprises the sequence of SEQ ID NO: 278 or variants thereof having at least about 95% sequence identity to said peptide.
21. The antibody according to claim 19 , wherein the variant has at least about 97% sequence identity to said non-native peptide.